BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Vorapaxar: Phase III amended

Merck said it will discontinue dosing in about a quarter of patients in the double-blind, placebo-controlled, international Phase III TRA-2P trial based on recommendations from a joint DSMB, but would not disclose additional details. The more than 20,000 patients who had experienced a previous heart attack or peripheral arterial disease (PAD) will...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >